ライフサイエンスコーパス: trabeculoplasty

1 ional surgery and approximately 5% had laser trabeculoplasty.

2 asty may be a better option than argon laser trabeculoplasty.

3 trabecular meshwork (TM) treatment by laser trabeculoplasty.

4 asonable and safe alternative to argon laser trabeculoplasty.

5 analogues, topical steroids, and argon laser trabeculoplasty.

6 t surgery (23.4% vs 12.3%; P < .0001), laser trabeculoplasty (18.6% vs 9.6%; P < .0001), and trabecul

7 IOP requiring medication or selective laser trabeculoplasty (25.9%) and mild-to-moderate keratitis (

8 gle of resolution vision or worse), and more trabeculoplasty (52% vs. 30%) among microstent eyes.

9 studies also found that SLT and argon laser trabeculoplasty (ALT) are equivalent in terms of safety

10 loplasty (SLT) was compared with argon laser trabeculoplasty (ALT) in a randomized clinical trial for

11 , 356 were randomised to the selective laser trabeculoplasty and 362 to the eye drops group.

12 ser trabeculoplasty, titanium sapphire laser trabeculoplasty and excimer laser trabeculotomy) have sh

13 Laser trabeculoplasty and glaucoma-filtering surgery are effic

14 Selective laser trabeculoplasty and medical therapy had similar outcomes

15 proposed mechanisms of action of argon laser trabeculoplasty and selective laser trabeculoplasty, as

16 itiated with ocular hypotensive drops, laser trabeculoplasty and surgery may also be used to slow dis

17 Laser trabeculoplasty and trabeculectomy also narrow the range

18 n for the treatment sequences of argon laser trabeculoplasty and trabeculectomy, and that lower intra

19 n of risk factors for failure of argon laser trabeculoplasty and trabeculectomy, and the impact of co

20 mage, patients could receive selective laser trabeculoplasty and trabeculectomy.

21 Medical therapy, laser trabeculoplasty, and filtration surgery each have their

22 imental glaucoma was produced by argon laser trabeculoplasty, and visual fields were assessed with be

23 Laser trabeculoplasty appears to rely on this process to resto

24 Argon laser and selective laser trabeculoplasty are safe and effective procedures for lo

25 ere was a 97% probability of selective laser trabeculoplasty as first treatment being more cost-effec

26 on laser trabeculoplasty and selective laser trabeculoplasty, as well as review current studies of th

27 A) glaucoma reoperation; (B) selective laser trabeculoplasty; (C) intraocular pressure (IOP) < 5 mmHg

28 Laser trabeculoplasty can reduce nocturnal IOP elevation in me

29 options for treating glaucoma include laser trabeculoplasty, cycloablation, trabeculectomy, and glau

30 glaucoma medications added, adjunctive laser trabeculoplasty, cyclodiode laser, or filtering surgery.

31 76 476 in 2005, but since 2005 the number of trabeculoplasties decreased 19% to 142 682 in 2012.

32 Laser trabeculoplasty did not alter the need for subsequent in

33 in whom pharmacologic treatment and/or laser trabeculoplasty do not suffice to control the intraocula

34 ificant for 4 of 6 procedures studied: laser trabeculoplasty (elasticity, -0.27; 95% confidence inter

35 thalmic Technology Assessment titled, "Laser Trabeculoplasty for Open-Angle Glaucoma," published in N

36 9.3-78.6) of patients in the selective laser trabeculoplasty group required no drops to maintain intr

37 re was 0.89 (SD 0.18) in the selective laser trabeculoplasty group versus 0.90 (SD 0.16) in the eye d

38 Eyes of patients in the selective laser trabeculoplasty group were within target intracoluar pre

39 Since the 1980s, laser trabeculoplasty has served as an effective way to lower

40 .01, 95% CI, 1.91-5.17) and past argon laser trabeculoplasty (HR 1.81, P < 0.01, 95% CI, 1.18-2.77).

41 group) and added therapy or selective laser trabeculoplasty in 4 eyes (3 in the cataract group and 1

42 Laser trabeculoplasty induces the expression and secretion of

43 Selective laser trabeculoplasty is a safe alternative but is rarely used

44 Selective laser trabeculoplasty is a safe treatment for OAG and OHT, pro

45 ve medical treatment for lowering IOP, laser trabeculoplasty is as effective as medical treatment as

46 gh there is good evidence that initial laser trabeculoplasty is just as effective as initial medical

47 sms by which argon laser and selective laser trabeculoplasty lower intraocular pressure are not known

48 Adjunctive laser trabeculoplasty (LT) is an alternative to topical medica

49 me, and iStent) with and without prior laser trabeculoplasty (< 2 years preceding MIGS) were identifi

50 Laser trabeculoplasty (LTP) is routinely used to treat open-an

51 stry to assess factors associated with laser trabeculoplasty (LTP) responses.

52 ng medications followed by 360 degrees laser trabeculoplasty (LTP), or to traditional mono-therapy, w

53 fectiveness with and without preceding laser trabeculoplasty (LTP).

54 ts have surgical privileges to perform laser trabeculoplasty (LTP).

55 are a few circumstances when selective laser trabeculoplasty may be a better option than argon laser

56 From 2001 to 2005, the number of trabeculoplasties more than doubled from 75 647 in 2001

57 in analogs (n = 2887/5120 [56.4%]) and laser trabeculoplasty (n = 705/5120 [13.8%]) were the most com

58 Laser trabeculoplasty of the anterior uveal region of the trab

59 ed randomisation) to initial selective laser trabeculoplasty or to eye drops.

60 tment with topical betaxolol and argon laser trabeculoplasty or to no initial treatment as long as no

61 Selective laser trabeculoplasty performed in 360 degrees, at an energy l

62 ts with early glaucoma either to argon laser trabeculoplasty plus betaxolol (n = 129) or to no immedi

63 Between 2000 and 2010, the rate of laser trabeculoplasty procedures provided by ophthalmologists

64 used to assess nonsurgical care, while laser trabeculoplasty procedures were used to assess clinic-ba

65 The mechanism by which laser trabeculoplasty reduces elevated intraocular pressure in

66 toperative periods to accompany laser (e.g., trabeculoplasty) reduces the risk of postoperative IOP s

67 Selective laser trabeculoplasty should be offered as a first-line treatm

68 Selective laser trabeculoplasty should be preferred as the first line of

69 rvention included history of selective laser trabeculoplasty (SLT) (P = 0.004; odds ratio [OR], 14.4)

70 2.32; 95% CI, 1.18-4.57) and selective laser trabeculoplasty (SLT) (RR, 1.25; 95% CI, 1.11-1.42) vers

71 coma medication, followed by selective laser trabeculoplasty (SLT) and eventually glaucoma surgery (T

72 d studies suggest a role for selective laser trabeculoplasty (SLT) as initial therapy for open-angle

73 e (IOP)-lowering efficacy of selective laser trabeculoplasty (SLT) as sole therapy for primary open-a

74 d the efficacy and safety of selective laser trabeculoplasty (SLT) compared with topical hypotensive

75 Recently, selective laser trabeculoplasty (SLT) has been demonstrated to lower the

76 ure (IOP) outcomes following selective laser trabeculoplasty (SLT) in early open-angle glaucoma (OAG)

77 Selective laser trabeculoplasty (SLT) is a common procedure to lower int

78 Selective laser trabeculoplasty (SLT) is a common treatment option for m

79 Selective laser trabeculoplasty (SLT) is a first-line treatment for glau

80 Selective laser trabeculoplasty (SLT) is a non-invasive treatment option

81 Selective laser trabeculoplasty (SLT) is a safe and effective treatment

82 To evaluate the influence of Selective Laser Trabeculoplasty (SLT) on iStent inject(R) outcomes in op

83 cy and safety of 360 degrees selective laser trabeculoplasty (SLT) on medically uncontrolled open-ang

84 rmine predictive factors for selective laser trabeculoplasty (SLT) outcome.

85 Selective laser trabeculoplasty (SLT) should be explored as a therapeuti

86 m efficacy of primary single-selective laser trabeculoplasty (SLT) to 0.005% latanoprost eye drops fo

87 sion (LiGHT) Trial has shown selective laser trabeculoplasty (SLT) to be clinically and cost-effectiv

88 The effectiveness of selective laser trabeculoplasty (SLT) was compared with argon laser trab

89 aimed to investigate whether selective laser trabeculoplasty (SLT) was superior to timolol eye drops

90 ickness (CCT), lack of prior selective laser trabeculoplasty (SLT), and male sex.

91 elease medication platforms, selective laser trabeculoplasty (SLT), and minimally invasive glaucoma s

92 dicated, treatments included selective laser trabeculoplasty (SLT), laser peripheral iridotomy (LPI),

93 including adding medication, selective laser trabeculoplasty (SLT), or incisional glaucoma surgery.

94 rformed on 8 eyes undergoing selective laser trabeculoplasty (SLT).

95 apy affected the efficacy of selective laser trabeculoplasty (SLT).

96 nalyze the results of repeat selective laser trabeculoplasty (SLT).

97 rates of resident-performed selective laser trabeculoplasty (SLT).

98 ety profile, and efficacy of selective laser trabeculoplasty (SLT).

99 y associated with history of selective laser trabeculoplasty (SLT, 0.40 [0.23-0.68] P = 0.0009) and l

100 erapy change eyes undergoing selective laser trabeculoplasty (SLT, n = 8 eyes), initiating topical th

101 Selective laser trabeculoplasty success was achieved in 227 eyes (22.8%)

102 Selective laser trabeculoplasty success was defined as IOP decrease of 2

103 Selective laser trabeculoplasty success was not significantly associated

104 previous acute angle closure attacks, laser trabeculoplasties, surgeries, or intraocular injections

105 Selective laser trabeculoplasty tended to achieve more IOP lowering than

106 l laser applications (micropulse diode laser trabeculoplasty, titanium sapphire laser trabeculoplasty

107 patients with previously failed argon laser trabeculoplasty treatment.

108 Laser trabeculoplasty use was less likely among patients at hi

109 Laser trabeculoplasty, using either photocoagulative (argon an

110 Argon laser trabeculoplasty, using typical clinical treatment parame

111 Laser trabeculoplasty was mainly performed for JOAG by nonglau

112 Selective laser trabeculoplasty was performed with 50 +/- 5 laser spots

113 centage of ophthalmologists performing laser trabeculoplasty was relatively stable (48% in 1995 to 50

114 surgical group, the odds of selective laser trabeculoplasty were reduced in patients with ocular hyp

115 ere treated with either medications or laser trabeculoplasty, whereas 72% (71/99) of the POAGS-to-POA

116 were excluded for prior filtration surgery, trabeculoplasty within 90 days of the OMNI procedure, or